MicroRNAs as crucial mediators in the pharmacological activities of triptolide (Review)

Exp Ther Med. 2021 May;21(5):499. doi: 10.3892/etm.2021.9930. Epub 2021 Mar 17.

Abstract

Triptolide is the main bioactive constituent isolated from the Chinese herb Tripterygium wilfordii Hook F., which possesses a variety of pharmacological properties. MicroRNAs (miRNAs/miRs) are short non-coding RNAs that regulate gene expression post-transcriptionally. miRNAs are implicated in several intracellular processes, whereby their dysregulation contributes to pathogenesis of various diseases. Thus, miRNAs have great potential as biomarkers and therapeutic targets for diseases, and are implicated in drug treatment. Previous studies have reported that specific miRNAs are targeted, and their expression levels can be altered following exposure to triptolide. Thus, miRNAs are emerging as crucial mediators in the pharmacological activities of triptolide. The present review summarizes current literature on miRNAs as target molecules in the pharmacological activities of triptolide, including antitumor, anti-inflammatory, immunosuppressive, renal protective, cardioprotective, antiangiogenesis activities and multiorgan toxicity effects. In addition, the diverse signaling pathways involved are discussed to provide a comprehensive understanding of the underlying molecular mechanisms of triptolide in the regulation of target miRNAs.

Keywords: anti-inflammatory; antiangiogenesis; antitumor; cardioprotective; immunosuppressive; microRNAs; multiorgan toxicity; renal protective; triptolide.

Publication types

  • Review

Grants and funding

Funding: The present review was supported by the Applied Basic Research Program of Science and Technology Department of Shanxi Province (grant no. 201801D121357), the Research Project of Shanxi Provincial Health and Family Planning Commission (grant no. 201601114) and the Research Fund from Shanxi Key Laboratory of Innovative Drug for Treatment of Serious Diseases Basing on the Chronic Inflammation (grant no. SXIDL-2018-08).